Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort

J. S.W. Borgers; F. H. Burgers; A. Schina; O. J. Van Not; A. J.M. van den Eertwegh; C. U. Blank; M. J.B. Aarts; F. W.P.J. van den Berkmortel; J. W.B. de Groot; G. A.P. Hospers; E. Kapiteijn; D. Piersma; R. S. van Rijn; A. M.Stevense den Boer; A. A.M. van der Veldt; G. Vreugdenhil; M. J. Boers-Sonderen; M. W.J.M. Wouters; K. P.M. Suijkerbuijk; J. V. van Thienen; J. B.A.G. Haanen

doi:10.1111/pcmr.13117

Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort

J. S.W. Borgers, F. H. Burgers, A. Schina, O. J. Van Not, A. J.M. van den Eertwegh, C. U. Blank, M. J.B. Aarts, F. W.P.J. van den Berkmortel, J. W.B. de Groot, G. A.P. Hospers, E. Kapiteijn, D. Piersma, R. S. van Rijn, A. M.Stevense den Boer, A. A.M. van der Veldt, G. Vreugdenhil, M. J. Boers-Sonderen, M. W.J.M. Wouters, K. P.M. Suijkerbuijk, J. V. van ThienenJ. B.A.G. Haanen^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.

Original language	English
Pages (from-to)	15-20
Number of pages	7
Journal	Pigment Cell & Melanoma Research
Volume	37
Issue number	1
Early online date	8 Aug 2023
DOIs	https://doi.org/10.1111/pcmr.13117
Publication status	Published - Jan 2024

Access to Document

10.1111/pcmr.13117Licence: CC BY-NC-ND

Cite this

Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M. S. D., van der Veldt, A. A. M., Vreugdenhil, G., Boers-Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., ... Haanen, J. B. A. G. (2024). Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort. Pigment Cell & Melanoma Research, 37(1), 15-20. https://doi.org/10.1111/pcmr.13117

@article{4b238e2fd6d6444b98aaf9d534ad9895,

title = "Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort",

abstract = "Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.",

author = "Borgers, {J. S.W.} and Burgers, {F. H.} and A. Schina and Van Not, {O. J.} and {van den Eertwegh}, {A. J.M.} and Blank, {C. U.} and Aarts, {M. J.B.} and {van den Berkmortel}, {F. W.P.J.} and {de Groot}, {J. W.B.} and Hospers, {G. A.P.} and E. Kapiteijn and D. Piersma and {van Rijn}, {R. S.} and Boer, {A. M.Stevense den} and {van der Veldt}, {A. A.M.} and G. Vreugdenhil and Boers-Sonderen, {M. J.} and Wouters, {M. W.J.M.} and Suijkerbuijk, {K. P.M.} and {van Thienen}, {J. V.} and Haanen, {J. B.A.G.}",

note = "Funding Information: No funding was obtained for this manuscript. The Dutch Institute for Clinical Auditing (DICA) foundation received a start-up grant for the Dutch Melanoma Treatment Registry (DMTR) from The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma ended their funding in 2019, and Pierre Fabre started funding the DMTR in 2019. Publisher Copyright: {\textcopyright} 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.",

year = "2024",

month = jan,

doi = "10.1111/pcmr.13117",

language = "English",

volume = "37",

pages = "15--20",

journal = "Pigment Cell & Melanoma Research",

issn = "1755-1471",

publisher = "Wiley-Blackwell",

number = "1",

}

Borgers, JSW, Burgers, FH, Schina, A, Van Not, OJ, van den Eertwegh, AJM, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Boer, AMSD, van der Veldt, AAM, Vreugdenhil, G, Boers-Sonderen, MJ, Wouters, MWJM, Suijkerbuijk, KPM, van Thienen, JV & Haanen, JBAG 2024, 'Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort', Pigment Cell & Melanoma Research, vol. 37, no. 1, pp. 15-20. https://doi.org/10.1111/pcmr.13117

TY - JOUR

T1 - Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort

AU - Borgers, J. S.W.

AU - Burgers, F. H.

AU - Schina, A.

AU - Van Not, O. J.

AU - van den Eertwegh, A. J.M.

AU - Blank, C. U.

AU - Aarts, M. J.B.

AU - van den Berkmortel, F. W.P.J.

AU - de Groot, J. W.B.

AU - Hospers, G. A.P.

AU - Kapiteijn, E.

AU - Piersma, D.

AU - van Rijn, R. S.

AU - Boer, A. M.Stevense den

AU - van der Veldt, A. A.M.

AU - Vreugdenhil, G.

AU - Boers-Sonderen, M. J.

AU - Wouters, M. W.J.M.

AU - Suijkerbuijk, K. P.M.

AU - van Thienen, J. V.

AU - Haanen, J. B.A.G.

N1 - Funding Information: No funding was obtained for this manuscript. The Dutch Institute for Clinical Auditing (DICA) foundation received a start-up grant for the Dutch Melanoma Treatment Registry (DMTR) from The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma ended their funding in 2019, and Pierre Fabre started funding the DMTR in 2019. Publisher Copyright: © 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.

PY - 2024/1

Y1 - 2024/1

N2 - Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.

AB - Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.

U2 - 10.1111/pcmr.13117

DO - 10.1111/pcmr.13117

M3 - Comment/Letter to the editor

SN - 1755-1471

VL - 37

SP - 15

EP - 20

JO - Pigment Cell & Melanoma Research

JF - Pigment Cell & Melanoma Research

IS - 1

ER -